Great discussions at rtx1 users’ e-symposium 2024 – Replay available
Last week we had the pleasure to host a very insightful symposium chaired by three ophthalmologists – Kiyoko Gocho, Chiara Eandi and Thomas Theelen. Seven clinical research teams who use the rtx1 camera for AO retinal imaging presented recent studies and case reports. They illustrated novel capabilities for examining patients’ retinas at the cellular and microvascular scale, and also discussed about standardization of methods for AO studies.
In RPE65 patients who underwent Luxturna therapy, we could see that after the induced detachment, cone cells stabilized at 2 weeks, and remained stable after 4 weeks – which was not observed with any other retinal examination.
[About Stagardt disease, at advanced atrophic stage] For a biomarker of progression, visual acuity doesn’t perform well here, while the foveal sparing measurement with rtx1 really shows a decline.
Several advances in AO imaging clearly emerged from this symposium. It is great to see that rtx1 is being used for an increasing number of assessments: it started with photoreceptors, now it is also RPE cells, atrophic border expansion, vessel microstructure and neurovascular response as we saw today. It is also interesting that several teams have endeavour to define standard imaging protocols and share guidelines with the community. It is an important progress that should benefit all users.
As a manufacturer, we support these efforts by improving the device. The event introduced new features of the rtx1 camera, that expand and streamline AO imaging.
In our protocol for retinitis pigmentosa, in total we acquire 21 images per eye. The new software makes the procedure really easy: it is very good for operators, and for patients too since it reduced the duration of the AO examination.
We express our gratitude to the chairs and to all the speakers for sharing their experience, latest findings and valuable insights.
The replay is available – 2h video with chapters
To get access, send us a request via this form